204 related articles for article (PubMed ID: 22340019)
21. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
Wedzicha JA; Calverley PM; Seemungal TA; Hagan G; Ansari Z; Stockley RA;
Am J Respir Crit Care Med; 2008 Jan; 177(1):19-26. PubMed ID: 17916806
[TBL] [Abstract][Full Text] [Related]
22. Is salmeterol/fluticasone propionate equivalent to tiotropium bromide in the treatment of COPD?
Gillissen A
Am J Respir Crit Care Med; 2008 Jul; 178(1):105; author reply 106-7. PubMed ID: 18565963
[No Abstract] [Full Text] [Related]
23. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
Hoshino M; Ohtawa J
Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
[TBL] [Abstract][Full Text] [Related]
24. A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011.
Betsuyaku T; Kato M; Fujimoto K; Hagan G; Kobayashi A; Hitosugi H; James M; Jones PW
Int J Chron Obstruct Pulmon Dis; 2013; 8():453-9. PubMed ID: 24124358
[TBL] [Abstract][Full Text] [Related]
25. Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities.
Kalhan R; Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; MacKnight SD; Hahn B
Int J Chron Obstruct Pulmon Dis; 2021; 16():1149-1161. PubMed ID: 33911860
[TBL] [Abstract][Full Text] [Related]
26. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
27. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease.
Hoshino M; Ohtawa J
Respiration; 2013; 86(4):280-7. PubMed ID: 23880883
[TBL] [Abstract][Full Text] [Related]
28. Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.
Keating GM; McCormack PL
Drugs; 2007; 67(16):2383-405. PubMed ID: 17983257
[TBL] [Abstract][Full Text] [Related]
29. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
Welsh EJ; Cates CJ; Poole P
Cochrane Database Syst Rev; 2013 May; (5):CD007891. PubMed ID: 23728670
[TBL] [Abstract][Full Text] [Related]
30. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
[TBL] [Abstract][Full Text] [Related]
31. Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment.
Davis JR; Kern DM; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
J Manag Care Spec Pharm; 2016 Mar; 22(3):293-304. PubMed ID: 27003559
[TBL] [Abstract][Full Text] [Related]
32. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
33. Which long-acting bronchodilator is most cost-effective for the treatment of COPD?
Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP
Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983
[TBL] [Abstract][Full Text] [Related]
34. Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations.
Hagiwara M; Delea TE; Stanford RH
Allergy Asthma Proc; 2014; 35(1):54-62. PubMed ID: 24433597
[TBL] [Abstract][Full Text] [Related]
35. Seretide: a pharmacoeconomic analysis.
Fritscher L; Chapman KR
J Med Econ; 2008; 11(3):555-70. PubMed ID: 19450105
[TBL] [Abstract][Full Text] [Related]
36. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
37. Respiratory-related medical expenditure and inpatient utilisation among COPD patients receiving long-acting bronchodilator therapy.
Cao Z; Zou KH; Baker CL; Su J; Paulose-Ram R; Durden E; Shi N; Shah H
J Med Econ; 2011; 14(2):147-58. PubMed ID: 21288057
[TBL] [Abstract][Full Text] [Related]
38. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
Baloira Villar A; Vilariño Pombo C
Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
[TBL] [Abstract][Full Text] [Related]
39. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
Akazawa M; Hayflinger DC; Stanford RH; Blanchette CM
Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
[TBL] [Abstract][Full Text] [Related]
40. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
